Diagnostic value of galectin-3 in heart transplant recipients with myocardial complications

Objective: to determine the diagnostic value of galectin-3 in transplant recipients with myocardial fibrosis and acute heart transplant rejection, verified by endomyocardial biopsy. Materials and methods. The study included 124 patients with end-stage heart failure. Their ages ranged from 16 to 71 (average 48 ± 12) years, of which 106 (85%) were men and 18 (15%) were women. From 2013 to 2016, these patients underwent a heart transplant procedure at the Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation. Analysis of endomyocardial biopsy specimens was used to verify acute cellular, humoral rejection and myocardial fibrosis of the heart transplant. Severity and nature of fibrosis was evaluated using a qualitative imaging technique. Galectin-3 concentration was measured by enzyme immunoassay using Human Galectin-3 Platinum ELISA reagent kits (Bender MedSystems GmbH, Vienna, Austria). Results. In the long-term post-transplantation period, in comparison with the early post-transplantation period, the number of verified graft myocardial fibrosis increased by 88% in recipients who had acute rejection crises and by 37% in recipients who had no rejection crises. Graft myocardial fibrosis was detected more often in recipients who had acute humoral rejection than in those who had acute cell rejection (92% vs 75% of cases, respectively). Plasma galectin-3 levels in recipients with graft myocardial fibrosis was higher than in recipients without it (p = 0.05 1 year and p = 0.01 1–5 years after heart transplantation). In recipients who had acute rejection crises, the risk of developing graft myocardial fibrosis was 1.64 (RR = 1.64 ± 0.1 [95% CI 1.1–2.2]). Conclusion. Galectin-3 is a biomarker for myocardial fibrosis in acute heart transplant rejection.

heart transplantation, galectin-3, myocardial fibrosis, acute rejection, diagnostic value

1. Shevchenko AO, Nikitina EA, Koloskova NN, Shevchenko OP, Gautier SV. Kontroliruemaja arterial’naja gipertenzija i vyzhivaemost’ bez nezhelatel’nyh sobytij u recipientov serdca. Kardiovaskuljarnaja terapija i profilaktika. 2018; 17 (4): 4–11. [In Russ, English abstract].

2. Lok SI, Nous FM, van Kuik J et al. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J Cardiothorac Surg. 2015; 48: 407–415.

3. Ahmad T, Wang T, O’Brien EC et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. J Am Coll Cardiol HF. 2015; 3: 30–39.

4. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006. 1760: 6616–6635.

5. González A, Schelbert EB, Díez J, Butler J. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. J Am Coll Cardiol. 2018; 71 (15): 1696–1706. doi: 10.1016/j.jacc.2018.02.02.

6. Drapkina OM, Deeva TA. Galektin-3 – biomarker fibroza u patsientov s metabolicheskim sindromom. Rossiyskiy kardiologicheskiy zhurnal. 2015; 9 (125): 96–102. [In Russ, English abstract].

7. Shevchenko OP, Ulybysheva AA, Gichkun OE, Mozheiko NP, Stakhanova EA, Kvan VS, Shevchenko AO. Galectin-3 in heart transplant rejection and fibrosis. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (3): 62–68. (In Russ.). https://doi.org/10.15825/1995-1191-2019-3-62-68.

8. Gautier SV, Shevchenko AO, Poptsov VN. Patsiyent s transplantirovannym serdtsem. M.–Tver’: Triada, 2014: 144. (In Russ.).

9. González A, López B, Ravassa S, San José G, Díez J. The Complex Dynamics of Myocardial Interstitial Fibrosis in Heart Failure. Focus on Collagen Cross-Linking. Biochim Biophys Acta Mol Cell Res. 2019; 1866 (9): 1421–1432.

10. Wan YJ, Guo Q, Liu D, Jiang Y. Protocatechualdehyde reduces myocardial fibrosis by directly targeting conformational dynamics of collagen. Eur J Pharmacol. 2019; 855: 183–191.

11. Gyongyosi M, Winkler J, Ramos I, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017; 19 (2): 177–191. doi: 10.1002/ejhf.696.

12. Kyselovic J, Leddy JJ. Cardiac Fibrosis: The Beneficial Effects of Exercise in Cardiac Fibrosis. Exercise for Cardiovascular Disease Prevention and Treatment: From Molecular to Clinical. 2017; Part 1: 257–268. doi: 10.1007/978-981-10-4307-9_14.